Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 87, Issue 4, Pages 372-375Publisher
WILEY
DOI: 10.1111/j.1600-0609.2011.01667.x
Keywords
chronic lymphocytic leukaemia; lenalidomide; 17p deletion; T-cell depletion; glucocorticoid; alemtuzumab
Categories
Ask authors/readers for more resources
Lenalidomide is an immunomodulatory agent with activity in a range of haematological cancers including chronic lymphocytic leukaemia (CLL). However, major questions remain concerning its effectiveness in patients with T-cell depletion or deletion of TP53 on chromosome 17p. This case report provides insight into these questions by showing that lenalidomide/dexamethasone in combination can be highly effective as induction therapy for refractory 17p- CLL, that remission quality can be improved by subsequent maintenance with lenalidomide alone and that the anti-leukaemic effects of lenalidomide and its stimulatory effects on non-malignant B cells are preserved despite prolonged T-cell depletion resulting from prior alemtuzumab/methylprednisolone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available